Last reviewed · How we verify
Azilect®
At a glance
| Generic name | Azilect® |
|---|---|
| Also known as | Rasagiline, rasagiline |
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability Study of HNC364 Injectable Suspension (PHASE1)
- Azilect® In Wearing-Off (AIWO)
- Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease (PHASE4)
- An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153) (PHASE3)
- Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China (PHASE3)
- Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease (PHASE4)
- Effect of Rasagiline on BIA 9-1067 Pharmacokinetics (PHASE1)
- A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azilect® CI brief — competitive landscape report
- Azilect® updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI